IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
� Earnings per Share
In the year end ing March 31 2008, earn ings per share at Takeda grew by 8.5% to Yen419.0 from
Yen386.0 the pre vi ous year.
Yen
450.0
400.0
350.0
300.0
250.0
200.0
150.0
100.0
50.0
0.0
Source: Takeda Annual Reports
� R&D Costs
Earnings Per Share
Spend ing on R&D in creased by 42.7% in the year to March 31 2008 to reach Yen276 bil lion, or 20.1% of
sales, up from Yen193 bil lion (14.8% of sales) in the pre vi ous year. This in crease was par tially due to li -
cense fees paid to Amgen.
Yen billions
300
250
200
150
100
50
0
Source: Takeda Annual Reports
2004 2005 2006 2007 2008
� Sales by Business Sector
R&D Costs
2004 2005 2006 2007 2008
Takeda’s busi ness was pre vi ously clas si fied into four seg ments, but since April 2003 the re struc tur ing and
divestments of sev eral non-core busi nesses have left the firm with just two seg ments: Pharmaceuticals
and Other. Within Pharmaceuticals, the com pany splits sales out fur ther into Eth i cal Drugs (split again
into Do mes tic and Over seas) and Con sumer Healthcare. The Other seg ment rep re sents the man u fac ture
and sales of lab o ra tory chem i cals and clin i cal di ag nos tic agents, spe cialty chem i cals, beverages and food,
among others.
© 2009 IMS Health In cor po rated or its af fil i ates Page 16